Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

ecancermedicalscience editor's choice for November 2014

Share :
Published: 28 Nov 2014
Views: 1466
Rating:
Save
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

Managing editor, Prof Gordon McVie, discusses the top articles from November 2014 published in ecancermedicalscience.

Articles mentioned are:

Report on the 9th EONS Congress, Istanbul, Turkey, 18–19 September 2014: nursing highlights

Hurdles and delays in access to anti-cancer drugs in Europe

Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine

Childhood leukaemia and lymphoma: African experience supports a role for environmental factors in leukaemogenesis

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )
25 Mar 2024
Hypofractionated high dose intensity modulated radiotherapy non-inferior for...
Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer ( Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK )
17 Feb 2023
Systemic anti-cancer performance matrix
Prof Richard Sullivan, Kari Leung and Megan McLeod
Systemic anti-cancer performance matrix ( Prof Richard Sullivan, Kari Leung and Megan McLeod )
23 Nov 2022
Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally...
Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium
Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )
11 Sep 2022
HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan
Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...
HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )
11 Sep 2022
Nirogacestat success for desmoid tumours
Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany
Nirogacestat success for desmoid tumours ( Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany )
10 Sep 2022
An overview of treatment advances in gastric cancer
Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA
An overview of treatment advances in gastric cancer ( Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA )
18 Aug 2022
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )
5 Jun 2022
High-dose ifosfamide standard of care for recurrent and primary refractory...
Dr Martin McCabe - University of Manchester, Manchester, England
High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )
5 Jun 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation